Ukoniq Alternatives Compared
| Ukoniq (umbralisib) | Rituximab | Rituxan (rituximab) |
|
|---|
| Ukoniq (umbralisib) | Rituximab | Rituxan (rituximab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Follicular Lymphoma, Marginal Zone Lymphoma. Ukoniq may also be used for purposes not listed in this medication guide. |
Prescription only
Rituximab (brand name Rituxan) is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia... View more |
Prescription only
Rituxan is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate and may be used to treat Non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid... View more |
||||||||
| More about Ukoniq (umbralisib) | More about Rituximab | More about Rituxan (rituximab) | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Rituximab has an average rating of 7.6 out of 10 from a total of 166 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 14% reported a negative effect. |
Rituxan has an average rating of 8.2 out of 10 from a total of 50 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Ukoniq side effects |
View all Rituximab side effects |
View all Rituxan side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Rituxan prices |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
||||||||
| Brand Names | ||||||||||
|
N/A |
Riabni, Rituxan, Ruxience, Truxima | Other rituximab brands include: Riabni, Ruxience, Truxima | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
91 hours |
59.8 hours |
59.8 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 195 drugs are known to interact with Ukoniq:
|
A total of 188 drugs are known to interact with Rituximab:
|
A total of 188 drugs are known to interact with Rituxan:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
February 05, 2021 |
N/A |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.